Navigation Links
ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
Date:4/10/2008

IRVINE, Calif., April 10 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today reported that it has received a subpoena from the United States Attorney's Office in Buffalo requesting the production of documents regarding promotional, educational and other activities relating to Xibrom(TM) (bromfenac sodium ophthalmic solution) 0.09%.

It is ISTA's policy to fully comply with all applicable U.S. and foreign laws, rules and regulations of governmental agencies or other authorities. In particular, the Company's code of conduct and legal compliance statutes are intended to ensure full compliance with all laws, rules and regulations governing the sale and marketing of pharmaceutical products.

ISTA plans to fully cooperate in responding to the subpoena.

About Ista Pharmaceuticals

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to bringing a new product to market every 12 to 18 months, and becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward- looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty of predicting the timing or outcome of product development efforts and the FDA or other regulatory agency approval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and or other governmental regulations applicable to ISTA's facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2007.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
2. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
3. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
4. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
5. ISTA Pharmaceuticals Engages Cowen as Financial Advisor
6. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
7. Barr Pharmaceuticals, Inc. Executive Bios
8. Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
9. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
10. MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
11. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a healthy lifestyle ... reasons. IsoPasta by Isolator Fitness has delved into this niche allowing those giving ... high-carb repercussions. IsoPasta has 30 grams of protein and only 7 grams of ...
(Date:2/13/2016)... ... 2016 , ... The producers of Enterprises TV are pleased to ... modern world of instantaneous consumption proves very convenient for businesses. With new technologies constantly ... coal, which pollutes our air, water, and soil. It can also threaten the lives ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... School of Nursing with an in-kind gift of a VeinViewer® Vision vein ... as they learn how to start an IV and draw blood, combining technology ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or ... groom themselves to perfection, go out of their way to be romantic, and may ... take a look at any online dating profile. , A recent study from ...
(Date:2/12/2016)... ... 12, 2016 , ... According to an article published February 4th ... significant portion of hernia repairs throughout the United States. Commenting on this article, Beverly ... that this trend has not only been expected, but it seems to be a ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Calif. , Feb. 12, 2016  Sequent Medical, ... in a study to evaluate the safety and effectiveness ... the treatment of ruptured intracranial aneurysms.  Prof Laurent ... Hospital, in Paris, France and ... patient. France and Germany.  ...
(Date:2/12/2016)... DIEGO and SEOUL, South ... Silicon Biosys­tems Menarini and Macrogen, Inc. today announced ... assays and innovative procedures for precision medicine in ... combine Silicon Biosystems, DEPArray™ digital-sorting technology with Macrogen,s ... of tests certified under the Clinical Laboratory Improvement ...
(Date:2/12/2016)... Ontario , Feb. 12, 2016  Aralez Pharmaceuticals ... pharmaceutical company, today announced the Company will ring the Nasdaq ... New York at 4:00 p.m. ... formation of Aralez. Adrian Adams , ... be held 3:50 to 4:00 p.m. ET.  A live ...
Breaking Medicine Technology: